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Exhaled nitric oxide thresholds associated with
a sputum eosinophil count $3% in a cohort of
unselected patients with asthma
Florence N Schleich,1 Laurence Seidel,2 Jocelyne Sele,1 Maite Manise,1
Valerie Quaedvlieg,1 Alain Michils,3 Renaud Louis1
ABSTRACT
Background It has been claimed that exhaled nitric oxide
(FeNO) could be regarded as a surrogate marker for
sputum eosinophil count in patients with asthma.
However, the FeNO threshold value that identifies
a sputum eosinophil count $3% in an unselected
population of patients with asthma has been poorly
studied.
Methods This retrospective study was conducted in 295
patients with asthma aged 15e84 years recruited from
the asthma clinic of University Hospital of Liege.
Receiver-operating characteristic (ROC) curve and
logistic regression analysis were used to assess the
relationship between sputum eosinophil count and FeNO,
taking into account covariates such as inhaled
corticosteroids (ICS), smoking, atopy, age and sex.
Results Derived from the ROC curve, FeNO $41 ppb
gave 65% sensitivity and 79% specificity (AUC¼0.777,
p¼0.0001) for identifying a sputum eosinophil count
$3%. Using logistic regression analysis, a threshold of
42 ppb was found to discriminate between eosinophilic
and non-eosinophilic asthma (p<0.0001). Patients
receiving high doses of ICS ($1000 mg beclometasone)
had a significantly lower FeNO threshold (27 ppb) than
the rest of the group (48 ppb, p<0.05). Atopy also
significantly altered the threshold (49 ppb for atopic vs
30 ppb for non-atopic patients, p<0.05) and there was
a trend for a lower threshold in smokers (27 ppb)
compared with non-smokers (46 ppb, p¼0.066). Age
and sex did not affect the relationship between FeNO
and sputum eosinophilia. When combining all variables
into the logistic model, FeNO (p<0.0001), high-dose ICS
(p<0.05) and smoking (p<0.05) were independent
predictors of sputum eosinophilia, while there was
a trend for atopy (p¼0.086).
Conclusion FeNO is able to identify a sputum eosinophil
count $3% with reasonable accuracy and thresholds
which vary according to dose of ICS, smoking and atopy.
INTRODUCTION
The utility of measuring airway inﬂammation in
the management of asthma has recently been
emphasised. Measuring exhaled nitric oxide (FeNO)
levels or the sputum eosinophil count in patients
with asthma in clinical practice was found to be
useful for diagnosis, predicting the response and
guiding the anti-inﬂammatory treatment.1 2 There
is evidence that a sputum eosinophil cell count of
3% is a robust biomarker that carries clinical value.
There is also increasing evidence that non-eosino-
philic asthma (sputum eosinophil count <2e3%) is
not improved by short-term treatment with
inhaled corticosteroids (ICS).3 Furthermore, in
longitudinal studies, targeting the sputum eosino-
phil count <2e3% for adjustment in the dose of
ICS in moderate to severe asthma results in
a marked reduction in asthma exacerbations and
hospitalisations.4 5 Online measurement of FeNO
has the advantage of being simple and providing
immediate results. Some studies, including ours,6e8
have shown a correlation between FeNO and
sputum eosinophil count in large unselected
populations of patients with asthma encountered
in daily practice. Berry et al found that a FeNO
value $8.3 ppb in non-smokers predicted a sputum
eosinophil count >3% when measured at a ﬂow
rate of 250 ml/s.6
Both FeNO levels and sputum eosinophils were
found to be strongly reduced by treatment with
ICS.9 10 It is well recognised that smoking lowers
FeNO values in patients with asthma,11 and some
studies have found that patients with asthma who
smoke are less eosinophilic than non-smoking
patients with asthma.12 Atopy was found to be
associated with raised FeNO irrespective of
asthma13 and is known to favour eosinophilic
inﬂammation. There are, however, no data on how
treatment with ICS, smoking and atopy may affect
the relationship between FeNO and sputum
eosinophil count.
We performed a retrospective analysis of a large
series of unselected patients with asthma who
underwent both FeNO determination and success-
ful sputum induction on the same visit. We deter-
mined FeNO values that best identiﬁed a sputum
eosinophil count $3%, taking into account impor-
tant covariates such as the dose of ICS, atopy,
smoking status, age and sex.
METHODS
Subject characteristics and study design
We conducted a retrospective study on a series of 357
patients with asthma recruited from the University
Asthma Clinic of Liege between 1 October 2005 and
30 September 2008. From those patients we selected
295 with asthma who had undergone both FeNO
measurement and successful sputum induction.
Their demographic and functional characteristics
are summarised in table 1. Patients attended the
clinic on 2 days at an interval of 1 week. On day 1
each patient underwent FeNO measurement,
spirometry with bronchodilation, sputum induc-
tion, gave a blood sample and ﬁlled in validated
asthma control and quality of life questionnaires.
See Editorial, p 1031
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On day 2 the subjects underwent methacholine challenge after
refraining from using bronchodilators for the appropriate time
(8 h for short-acting bronchodilators and 24 h for long-acting
bronchodilators) as long as the baseline forced expiratory volume
in 1 s (FEV1) value was not less than 70% predicted. Asthma was
diagnosed based on symptoms of cough, breathlessness or dys-
pnoea together with the demonstration of airﬂow variability. The
latter was deﬁned by airway hyper-responsiveness shown by one
or more of the following: increase in FEV1 of $12% and 200 ml
following inhalation of 400 mg salbutamol or inhaled concentra-
tion of methacholine provoking a 20% fall in FEV1 of<16 mg/ml.
Methacholine challenges were performed according to a stand-
ardised methodology as previously described.14 Subjects were
characterised as atopic if they had at least one positive speciﬁc IgE
(>0.35 kU/l; Phadia) for at least one common aeroallergen (cat,
dog, house dust mite, grass pollen, tree pollen and a mixture of
moulds). Quality of life was assessed using the self administered
Asthma Quality of Life Questionnaire (AQLQ)15 and asthma
control by the Juniper ACQ.16
Exhaled NO measurement, sputum induction and processing
FeNO was measured by chemiluminescence using a nitric oxide
monitor set at an exhalation ﬂow rate of 50 ml/s according to
the ERS/ATS recommendations (NIOX, Aerocrine, Sweden).
FeNO was measured prior to lung function tests, salbutamol
administration and induced sputum.
Sputum was induced and processed as previously reported.17
Cell counts were estimated on samples centrifuged (Cytospin)
and stained with Diff Quick after counting 500 cells (Dade,
Brussels, Belgium).
Statistical analyses
The results were expressed as mean6SD for continuous vari-
ables; median and interquartile range (IQR) were preferred for
skewed distributions. For categorical variables, the number of
observations and percentages were given in each category.
Comparisons between different subgroups were performed with
a KruskaleWallis test. The Spearman correlation coefﬁcient was
used to measure the association between FeNO and sputum
eosinophil count. The receiver-operating characteristic (ROC)
curve was constructed to determine the concentration of FeNO
which best identiﬁed a sputum eosinophil count $3% in the
whole population. Logistic regression analysis was used to assess
the relationship between the binary outcome (sputum eosino-
phil count $3%) and a set of covariates, individually or in
combination. Covariates included FeNO (log-transformed), age,
gender, smoking, ICS and atopy. Cut-off points on the FeNO
scale were determined in each case so that there was a $50%
probability of a sputum eosinophil count $3%. The sensitivity,
speciﬁcity, positive predictive value (PPV) and negative predic-
tive value (NPV) were also calculated for each cut-off point from
the original data. The results were considered to be signiﬁcant at
the 5% critical level (p<0.05). Calculations were done using SAS
Version 9.1 (SAS Institute, Cary, North Carolina, USA).
RESULTS
The demographic and functional characteristics of the patients
are given in table 1. For the whole group there was a signiﬁcant
positive relationship between the FeNO level and the percentage
of sputum eosinophil count (RS¼0.54, p<0.0001; ﬁgure 1).
Despite this signiﬁcant correlation, some patients showed
marked discordance between the two markers. Patients with
low sputum eosinophilia (<25% percentile) and high FeNO
levels (>75% percentile) were all atopic, non-smokers and
receiving low doses of ICS (N¼4). By contrast, for patients with
high sputum eosinophilia (>75% percentile) and low levels of
FeNO (<25% percentile), the only common distinctive feature
was high doses of ICS (N¼3). Using the ROC curve method we
found that a FeNO concentration >41 ppb yielded 65% sensi-
tivity and 79% speciﬁcity (AUC¼0.78, p<0.0001) for identifying
a sputum eosinophil count $3% in the whole population
(ﬁgure 2). This was conﬁrmed by logistic regression analysis as
we found that a threshold of 42 ppb discriminated between
eosinophilic and non-eosinophilic asthma with 63% sensitivity
and 80% speciﬁcity (p<0.0001).
Demographic, functional and inﬂammatory characteristics
according to smoking status and the dose of ICS are given in
table 2. When taking the dose of ICS into account in non-
smokers, we distinguished four groups: steroid-naïve patients
Table 1 Demographic, functional and inflammatory
characteristics of study patients (n¼295)
Characteristics
Sex (M/F) 131/164





IgE, kU/l 169 (53e472)
Blood eosinophils, % 3.8063.4
FEV1, % predicted 86619
FEV1/VC, % 75611
PC20, mg/ml 3.32 (0.025e16)
Reversibility, % 13.1612.5
Sputum eosinophils, % 1.8 (0.2e9.4)
Sputum neutrophils, % 43.6 (17.8e68.8)
FeNO, ppb 31 (15e62)
ACQ 1.8461.2
AQLQ 4.7761.3
Data are presented as mean6SD or median (IQR); PC20 is expressed as
geometric mean (range).
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life
Questionnaire; FeNO, exhaled nitric oxide; FEV1, forced expiratory
volume in 1 s; PC20, concentration required to provoke a fall in FEV1 of
20% or more; VC, vital capacity.
Figure 1 Evaluation of the relationship between sputum eosinophil
count and exhaled nitric oxide (FeNO) concentration in a cohort of
unselected patients with asthma (n¼295) by Spearman correlation.
There was a highly significant correlation between these two parameters
(p<0.0001, R¼0.54). ICS, inhaled corticosteroids.
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and patients receiving low doses of ICS (#500 mg/day beclo-
metasone), moderate doses (500e1000 mg/day beclometasone)
and high doses of ICS (>1000 mg/day beclometasone). These
groups had signiﬁcantly different median FeNO values, reaching
47 ppb, 46 ppb, 32 ppb and 24 ppb in steroid-naïve patients and
those on low, moderate and high ICS doses, respectively
(p<0.001, table 2). By contrast, there was no signiﬁcant differ-
ence in sputum eosinophil counts between the four groups
(2.8% (IQR 0.8e14.4) in steroid–naïve patients, 1.8% (IQR
0e12.2) in patients on low-dose ICS, 1.0% (IQR 0e10.3) in
patients on moderate doses and 1.8% (IQR 0.3e7.4) in the high-
dose ICS group (p>0.05, table 2). Using logistic regression we
found that the FeNO threshold associated with sputum eosin-
ophils $3% for patients receiving high doses of ICS was
signiﬁcantly lower (27 ppb) than that of steroid-naïve patients
or those receiving low and moderate doses of ICS (48 ppb,
p¼0.028, table 3).
Median FeNO in atopic subjects was 1.3 times higher (34 ppb)
than in non-atopic patients (26 ppb), which is close to that
reported by Travers et al (1.2 times, p¼0.011).18 By contrast, the
sputum eosinophil count did not differ between atopic and non-
atopic asthmatic subjects (median 1.8% vs 2%, p¼0.543). Using
logistic regression, atopic patients had a signiﬁcantly greater
FeNO threshold value (49 ppb) than non-atopic patients
(30 ppb, p¼0.049) to identify sputum eosinophils $3% (table 3).
The FeNO level in smokers was signiﬁcantly lower than in
non-smokers (median 17 ppb for smokers vs 35 ppb for non-
smokers, p¼0.003). The median FeNO level for non-smokers
was two times higher than in current smokers, which was
higher than 1.18 obtained by Travers et al18 but in line with the
results of Michils et al.19 In contrast, the median (IQR) sputum
eosinophil count did not differ signiﬁcantly between smokers
and non-smokers (1.7 (0.2e8) vs (1.8 (0.2e10.7); p¼0.765). After
logistic regression the FeNO level that identiﬁed a sputum
eosinophil count of $3% was lower in smokers than in non-
smokers (28 ppb vs 46 ppb, p¼0.066, table 3).
The median FeNO value was 1.33 times greater in men than
in women (36 ppb vs 27 ppb, p¼0.009), which is in keeping with
the results of Travers et al (1.24 times).18 The sputum eosinophil
count was greater in men than in women (2.9% vs 1.5%,
p¼0.042). However, the FeNO threshold that best identiﬁed
a sputum eosinophil count of $3% was not signiﬁcantly
different between men and women (table 3). Likewise, age did
not inﬂuence the relationship between FeNO and sputum
eosinophils.
When combining all variables into the logistic model, FeNO
(p<0.0001), high-dose ICS (p¼0.019) and smoking (p¼0.044)
were independent predictors of sputum eosinophilia and there
Figure 2 Receiver-operating characteristic curve (ROC) for the whole
group to determine the exhaled nitric oxide (FeNO) value which best
identified a sputum eosinophil count of $3%. The optimum cut-off point
was 41 ppb (point A, sensitivity 65%, specificity 79%). FeNO levels
>25 ppb gave a sensitivity of 78% and a specificity of 60% for
identifying a sputum eosinophil count $3% (point B, positive predictive
value (PPV) 59%, negative predictive value (NPV) 79%). FeNO values
>50 ppb gave a sensitivity of 56% and a specificity of 86% for
identifying a sputum eosinophil count $3% (point C, PPV 75%, NPV
73%). AUC, area under the curve.




Steroid-naı¨ve Low ICS Moderate ICS High ICS
N 58 70 41 67 59
Sex (M/F) 31/27 26/44 17/24 33/34 24/35
Age, years 45.7 (23e81) 42.3 (14e80) 47 (19e80) 47 (16e83) 50.5 (18e82)
Height, cm 170.567.8 16969.5 169.2611 16769.7 167.769.2
Weight, kg 73.3614 73616 74.3618 72.6614 72.9617.9
Atopy 72% 80% 71% 67% 61%
IgE, kU/l 185 (56e612) 166 (39e358) 210 (60e391) 180 (48e606) 132 (70e430)
Blood eosinophils, % 3.6063.5 3.8763.4 3.9463.2 3.9663.5 3.2663.26
FEV1, % predicted 81619 90616 93618 87620 78619
FEV1/VC, % 72610 7869 78610 75611 72612
PC20, mg/ml 4.23 (0.03e16) 2.17 (0.05e16) 6.6 (0.30e16) 3.93 (0.2e16) 2.3 (0.1e16)
Reversibility, % 15611 15.3614.8 12.168.5 13.3614.3 11.1611.7
Sputum eosinophils, % 1.7 (0.2e8) 2.8 (0.8 e 14.4) 1.8 (0 e 12.2) 1 (0 e 10.3) 1.8 (0.25 e 7.4)
Sputum neutrophils, % 43.1 (17.6 e 63.8) 41.7 (13 e 65.8) 32 (16.4 e 49.5) 45 (22.7 e 73.9) 52.5 (29.1 e 75.1)
FeNO, ppb 17 (12e37) 47 (23e87) 46 (21e75) 32 (13e61) 24 (12e45)
ACQ 2.3661.2 1.5761.1 1.3460.9 1.6961.1 2.1661.3
AQLQ 4.3961.28 5.1861.17 5.1561.1 4.7461.37 4.461.35
Data are presented as mean6SD or median (IQR); PC20 is expressed as geometric mean (range).
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FeNO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; PC20,
concentration required to provoke a fall in FEV1 of 20% or more; VC, vital capacity.
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was a trend for atopy (p¼0.086), but age and sex were not
signiﬁcant (table 4). The optimal cut-off point for FeNO asso-
ciated with a sputum eosinophil count >3% ranged from 15 ppb
for smoking non-atopic patients receiving a high dose of ICS to
58 ppb for non-smoking atopic patients not treated with a high
dose of ICS.
We compared our FeNO values in patients with asthma with
those expected based on the equation proposed by Dressel et al20 in
a general population, taking into account the height, sex, atopy
and smoking status. It appeared that our observed values were
much higher than expected, which highlights the importance of
asthma as a major factor contributing to the rise in FeNO (table 5).
DISCUSSION
Although the debate is not over, it is generally accepted that
FeNO has the potential to assess the phenotype of airway
inﬂammation. Like those of Berry et al,6 our data show that
FeNO can effectively identify sputum eosinophilia in a large
cohort of unselected patients with asthma. There is, however,
clear variation in the threshold associated with a sputum
eosinophil count of $3% depending on treatment with ICS,
atopy and smoking status.
The technique of induced sputum that allows collection of
airway cells has contributed to the emergence of the concept of
asthma phenotypes.21 In particular, it appeared that eosinophilic
asthma may show a different response to treatment with ICS
than non-eosinophilic asthma.22 Although introduced in the
early 1990s, the technique has not been widely adopted into
clinical practice, probably because it is technically demanding
and time-consuming.
Given the recognised clinical value of sputum eosinophil
count, we wondered whether FeNO measured at a ﬂow rate of
50 ml/s could effectively identify a sputum eosinophil count
>3% in a large cohort of unselected patients with asthma with
different disease severity. Overall we found that FeNO was
a valuable measurement to identify eosinophilic asthma with
a threshold value of 41 ppb, having sensitivity and speciﬁcity of
65% and 79% respectively. This threshold is twice as high as the
level recommended for an asthma diagnosis (20 ppb) but quite
close to the level that Smith et al claimed to predict a positive
response to ICS (47 ppb).23 This is also in keeping with the fact
that having a sputum eosinophil count of at least 3% is asso-
ciated with a clinical response to short-term treatment with
ICS. Coincidently, our threshold of 41 ppb appears to be the
same as the upper limit of the 90% CI found in a normal
population.18 There is an emerging consensus that FeNO values
>50 ppb indicate active eosinophilic airway inﬂammation.24
Conversely, FeNO values <25 ppb are associated with minimal
airway eosinophilia. According to our data, FeNO <25 ppb has
a negative predictive value of 79% for signiﬁcant airway
eosinophilic inﬂammation and FeNO >50 ppb has a positive
predictive value of 75% to identify sputum eosinophilia.
It is well established that chronic treatment of asthma with
ICS results in a reduction in airway eosinophilia10 25 together
with a fall in FeNO.9 26 27 How this treatment may affect the
relationship between sputum eosinophilia and FeNO remains
unclear, however. Our data indicate that FeNO is more sensitive
than the sputum eosinophil count to ICS as patients receiving
higher doses of ICS had lower FeNO values than the other
groups, a phenomenon not observed with the sputum eosinophil
count. Consequently, the FeNO threshold associated with
sputum eosinophilia $3% will be lower in patients receiving
high doses of ICS than in those not treated or receiving low or
medium doses of ICS.
Table 3 Simple logistic regression analysis assessing the effect of
















Yes 27 62 76 59 78 0.028
No 48 84 56 72 72
Atopy Yes 49 84 56 72 72 0.049
No 30 64 74 60 77
Smoking Yes 28 62 76 59 78 0.066
No 46 82 58 70 73
Male Yes 37 71 66 63 74 0.236
No 48 84 56 72 72
Age $40 43 80 62 69 74 0.873
<40 42 79 64 69 75
Age and sex did not contribute significantly to the predictive value of FeNO (for more details
on calculation see online supplement).
FeNO, exhaled nitric oxide; ICS, inhaled corticosteroids. NPV, negative predictive value;
PPV, positive predictive value
Table 4 Cut-off points for FeNO for predicting a sputum eosinophil
















No No No 38 74 66 65 75
No No Yes 24 59 78 58 79
No Yes No 58 88 48 74 70
No Yes Yes 35 71 70 64 76
Yes No No 23 58 78 58 78
Yes No Yes 15 37 94 52 89
Yes Yes No 33 68 70 62 76
Yes Yes Yes 20 54 85 58 83
When combining all variables into the logistic model, only FeNO (p<0.0001), smoking
(p¼0.044) and ICS (p¼0.019) were significant predictors of a sputum eosinophil count
$3%. When atopy was added the p value was not significant although a trend was
observed (p¼0.086) (for more details on calculation see online supplement).
FeNO, exhaled nitric oxide; ICS, inhaled corticosteroids; NPV, negative predictive value;
PPV, positive predictive value.
Table 5 Comparison of exhaled nitric oxide (FeNO) values measured in
patients with asthma with those expected based on the formula





































*FeNO (ppb)¼17.493(1.496 if atopy)3(0.627 if smoker)3(1.235 if infection)3(1.174 if
male)31.113 (height cm-170)/10)). Our observed values were much higher than expected,
which highlights the importance of asthma as the major factor contributing to raised FeNO.
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In agreement with previous studies,13 the inﬂuence of atopy
was evident in our study with a 30% increase in FeNO in atopic
compared with non-atopic patients with asthma. On the other
hand, the sputum eosinophil count was similar in both groups.
Consequently, the FeNO threshold associated with sputum
eosinophilia was found to be greater in atopic patients with
asthma than in non-atopic patients with asthma.
Interestingly, our data show that sputum eosinophilia may be
present in subjects with asthma who smoke. Indeed, the median
value in asthmatics who smoke was not signiﬁcantly lower than
that in the non-smoking group, which is consistent with the
ﬁndings of Boulet et al.28 There are no data showing that
starting to smoke reduces the sputum eosinophil count in
patients with asthma. There are, however, data showing that
smoking cessation in asthma does not impact on the sputum
eosinophil count.29 In contrast, the FeNO levels were clearly
lower in patients with asthma who smoke, which conﬁrms the
results of a previous study.11 This may be explained by partial
irreversible inhibition of nitric oxide synthase by cigarette smoke
extract,30 31 or by conversion of nitric oxide to peroxynitrite by
superoxide release from neutrophils.32 As tobacco inﬂuences
FeNO and the sputum eosinophil count differently, it therefore
changes the FeNO cut-off value.
As expected, we found higher FeNO levels in men than in
women. Interestingly, the sputum eosinophil count was lower
in women than in men, an observation not previously reported
and in keeping with the higher proportion of neutrophilic
asthma in women.33 The reasons for this are unclear at present
but might be linked to different immunological mechanisms
governing airway inﬂammation.34 Although sex may inﬂuence
both the FeNO and the sputum eosinophil count, it does not
alter the relationship between these two variables.
As several parameters were shown to inﬂuence the relation-
ship between FeNO and sputum eosinophils, a multiple logistic
regression approach was used to determine the most useful cut-
off point in a patient. It conﬁrmed the importance of high-dose
ICS and smoking and, to a lesser extent, atopy. We found that
the optimal cut-off points varied from 15 ppb for smoking non-
atopic patients receiving a high dose of ICS to 58 ppb for non-
smoking atopic patients not treated with a high dose of ICS.
The gap between these two extremes is large and ought to be
taken into account in the interpretation of airway inﬂammation.
Some of our patients had paucigranulocytic asthma35 and still
exhibited raised FeNO levels. This discordance might be
explained by inﬂammation which has not spilled over into the
airway lumen, such that induced sputum is negative for eosin-
ophils while this cell type still persists in the airway wall. In
these patients, monitoring of FeNO could be more informative
than measuring sputum eosinophils.
While it is a reasonable assumption that our derived FeNO
cut-off values will be applicable to the general asthma popula-
tion, further work is required to validate this in practice as we
did not divide our dataset into training and testing groups.
CONCLUSION
FeNO is able to identify the presence of sputum eosinophilia in
unselected patients with asthma with reasonable accuracy as
long as thresholds are adjusted for high doses of ICS, atopy and
smoking status.
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Lung alert
Utility of serum and sputum calprotectin as a biomarker
for CF exacerbation
Monitoring inﬂammation and diagnosing pulmonary exacerbation in cystic ﬁbrosis (CF)
remains difﬁcult as the usual biomarkers of inﬂammation are often not very helpful and there
is still no accepted deﬁnition for a CF exacerbation. This study looked at the possibility of
serum and sputum calprotectin as a new biomarker for monitoring pulmonary exacerbations
in CF.
It was hypothesised that serum and sputum calprotectin will change informatively during
the CF exacerbation. Twenty-seven patients completed the study. Sputum was tested for
calprotectin, interleukin 8 (IL-8), myeloperoxidase (MPO) and neutrophils at the beginning
and the end of treatment. Serum was tested for calprotectin, white cell count, C-reactive
protein (CRP) and vascular endothelial growth factor (VEGF). Case notes were reviewed
a year after completion of the study to calculate the time to the next exacerbation.
Sputum calprotectin was signiﬁcantly reduced (p<0.05) with treatment. MPO and IL-8 also
decreased with treatment but the trend was not signiﬁcant. In serum, calprotectin, CRP and
VEGF were all reduced signiﬁcantly with treatment (p¼0.002, p¼0.002 and p¼0.013.
respectively). Serum calprotectin and CRP were both negatively correlated with the forced
expiratory volume in 1 s (FEV1) but the correlation was much stronger for calprotectin. For
a calprotectin level of $9.1 mg, the median time to the next exacerbation was 70 days,
whereas for a level of <9.1 it was 112 days. CRP failed to show a difference in median time to
next exacerbation with the cut-off value of 10.
This study shows that calprotectin is a better biomarker for inﬂammation in the CF lung
and could be useful in monitoring the exacerbations and response to treatment. It can also be
useful in predicting the time to the next exacerbation.
< Gray RD, Imrie M, Boyd AC, et al. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros
2010;9:193e8.
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